Scholar Rock (NASDAQ: SRRK) announced that the U.S. Food and Drug Administration has approved ISEMBYLD (apitegromab-mstn) for the treatment of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA